design
produc
selfassembl
protein
nanoparticl
selfassembl
protein
nanoparticl
contain
five
supertypesrestrict
epitop
antigen
express
toxoplasma
gondii
lifecycl
univers
cell
epitop
padr
flagellin
scaffold
agonist
cell
epitop
separ
nkaaa
spacer
optim
proteasom
cleavag
selfassembl
protein
nanoparticl
adjuv
ligandemuls
glase
evalu
efficaci
induc
respons
protect
hlaa
transgen
mice
gondii
immun
use
selfassembl
protein
nanoparticleglas
activ
cell
produc
selfassembl
protein
nanoparticleglas
also
protect
hlaa
transgen
mice
subsequ
challeng
type
ii
parasit
henc
combin
cellelicit
peptid
padr
multiepitop
protein
form
nanoparticl
administ
glase
lead
effici
present
major
histocompat
complex
class
ii
molecul
furthermor
result
suggest
activ
could
use
develop
vaccin
elicit
cell
prevent
toxoplasmosi
human
toxoplasma
gondii
infect
mammal
caus
sever
brain
eye
damag
fetu
newborn
infant
immunecompromis
individu
although
antiparasit
medicin
sulfadiazin
pyrimethamin
avail
patient
experi
side
effect
includ
toxic
hypersensit
latent
encyst
parasit
elimin
treatment
therefor
develop
potent
safe
effect
vaccin
greatli
need
one
approach
toxoplasmosi
vaccin
develop
epitopebas
vaccin
design
enhanc
host
immun
protect
achiev
stimul
helper
lymphocyt
produc
lymphocyt
respons
cell
recogn
octamernonam
peptid
present
hla
supermotif
molecul
infect
cell
previous
laboratori
rm
ke
identifi
epitop
elicit
cell
deriv
protein
express
differ
phase
toxoplasma
life
cycl
human
supermotif
major
histocompat
complex
mhc
molecul
present
human
therefor
capabl
present
epitop
discoveri
protect
peptid
epitop
accumul
mechan
need
effect
present
epitop
immun
system
host
pioneer
platform
known
selfassembl
protein
nanoparticl
sapn
sapn
induc
strong
immun
respons
due
repetit
display
antigen
promot
immun
respons
well
cell
incorpor
cell
epitop
core
architectur
nanoparticl
trigger
strong
innat
immun
respons
activ
pathway
adjuv
flagellin
size
shape
potenti
reach
follicular
dendrit
cell
critic
antigen
present
process
although
macrophag
play
role
immun
interact
sapn
macrophag
studi
sapn
induc
immun
respons
order
magnitud
stronger
keyhol
limpet
hemocyanin
standard
vaccin
carrier
previous
design
sapnbas
vaccin
candid
variou
infecti
diseas
includ
malaria
hiv
sar
influenza
earlier
find
recent
parallel
work
recombin
polypeptid
sapn
glase
fig
unpublish
data
dl
provid
foundat
present
studi
earlier
find
provid
basi
use
immunosens
select
peptid
differ
genet
isol
gondii
fig
flagellin
scaffold
adjuv
glase
earlier
studi
walter
reed
armi
institut
research
malaria
base
sapn
demonstr
flagellin
molecul
improv
immunogen
dl
pb
unpublish
work
initi
basi
use
flagellin
sapn
scaffold
gondii
studi
fig
approach
also
use
work
influenza
work
suggest
flagellin
would
help
scaffold
immunogen
newest
gondii
work
experi
provid
signific
part
foundat
approach
sapn
protect
toxoplasmosi
dl
pb
unpublish
work
found
follow
glase
glaselik
adjuv
need
produc
signific
titer
antinanoparticl
antibodi
purifi
igg
immun
monkey
complet
protect
mice
challeng
lethal
dose
sporozoit
express
fulllength
plasmodium
falciparum
circumsporozoit
protein
purifi
igg
control
monkey
protect
mice
purifi
igg
immun
monkey
mix
p
falciparum
sporozoit
prevent
sporozoit
infect
primari
hepatocyt
human
liver
tissu
cultur
igg
control
monkey
thu
use
preliminari
foundat
data
chose
glase
adjuv
studi
herein
glase
two
compon
gla
se
gla
hydrophob
use
alon
formul
gla
would
excipi
make
formul
nonequival
gla
earlier
studi
demonstr
emuls
call
se
adjuv
protein
administ
alon
present
glase
preclin
studi
clinic
trial
adjuv
prevent
cancer
herp
leishmania
mycobacterium
tuberculosi
infect
earlier
studi
also
demonstr
glase
superior
alum
adjuv
polypeptid
glase
also
superior
alum
primat
immun
sapn
fact
alum
diminish
respons
glase
plu
sapn
dl
pb
unpublish
work
previou
studi
gondii
construct
sapn
display
dens
granul
epitop
pandr
bind
epitop
padr
evalu
vaccin
compon
hlab
transgen
mice
immun
mice
activ
cell
produc
therebi
mice
protect
subsequ
challeng
high
inocula
type
type
ii
parasit
initi
result
highlight
potenti
protect
toxoplasmosi
sapn
vaccin
approach
present
studi
five
epitop
bind
evalu
efficaci
sapnvaccin
transgen
mice
includ
epitop
surfac
antigen
dens
granul
protein
surfac
sequenc
construct
supertypesrestrict
epitop
link
nkaaa
spacer
conjug
padr
univers
helper
lymphocyt
epitop
synthet
polypeptid
effect
mice
effect
pool
peptid
separ
padr
bind
promiscu
mhc
class
ii
variant
augment
effector
function
cell
stimul
product
helper
cell
epitop
elicit
cell
import
compon
formul
success
vaccin
drive
protect
respons
data
show
incorpor
padr
sapn
construct
deliv
ligand
emuls
adjuv
glase
result
activ
cell
vaccin
formul
led
cell
produc
protect
subsequ
challeng
type
ii
parasit
given
high
inoculum
thu
work
highlight
potenti
use
sapn
platform
deliveri
restrict
epitop
formul
glase
adjuv
protect
toxoplasmosi
prepar
character
sapn
emptysapn
sapn
construct
express
purifi
fold
form
nanoparticl
fig
protein
rel
molecular
weight
kda
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
fig
e
transmiss
electron
microscopi
fig
show
rel
uniform
distribut
nonaggreg
nanoparticl
nm
diamet
vivo
immunogen
cellelicit
sapn
hlaa
mice
immun
intramuscularli
cellelicit
sapn
combin
glase
mice
immun
three
time
intramuscularli
week
interv
emptysapn
plu
glase
pb
use
sham
immun
control
mice
cellelicit
sapnglas
vs
emptysapnglas
compar
hlaa
transgen
mice
describ
spleen
cell
obtain
immun
hlaa
transgen
mice
week
final
immun
produc
splenocyt
cultur
pool
peptid
measur
figur
show
secret
high
mice
immun
cellelicit
sapn
plu
glase
stimul
padr
peptid
peptid
also
elicit
product
earlier
work
herein
effect
separ
peptid
addit
fig
polyepitop
elicit
best
respons
earlier
herein
fig
figur
b
indic
secret
cultur
peptid
significantli
enhanc
immun
peptid
emptysapn
pb
significantli
secret
observ
cell
stimul
pool
peptid
plu
padr
thu
associ
celland
cellrestrict
peptid
contribut
product
hlaa
transgen
mice
vitro
stimul
seaport
celllin
expos
vari
concentr
sapn
sapn
includ
emptysapn
contain
epitop
still
flagellin
sapn
contain
polypeptid
five
restrict
epitop
recombin
polypeptid
recombin
flagellin
control
concentr
sapn
use
ngml
fold
increas
seap
express
protein
sampl
nontreat
control
reflect
level
stimul
shown
fig
c
activ
fig
assembl
phylogenet
tree
show
genet
isol
toxoplasma
analyz
herein
multisequ
align
protein
peptid
deriv
util
creat
artifici
immunogen
smart
protein
b
flagellin
use
scaffold
epitop
intercal
toxoplasma
earlier
logic
inclus
flagellin
adjuv
scaffold
came
work
malaria
http
infectiousdiseasesresearchmedialrpdf
well
influenza
comput
model
prototyp
core
particl
compos
pentamer
trimer
coil
coil
shown
green
blue
respect
follow
attach
trimer
coil
coil
agonist
flagellin
domain
purpl
epitop
yellow
epitop
string
magenta
c
sdspage
purifi
protein
lane
follow
lane
mw
molecular
weight
marker
lane
elut
fraction
sampl
deriv
experi
gelsblot
process
parallel
transmiss
electron
microscopi
nanoparticl
prepar
e
sdspage
purifi
protein
lane
mw
molecular
weight
marker
lane
lane
emptysapn
sampl
deriv
experi
gelsblot
process
parallel
significantli
enhanc
emptysapn
cellelicit
sapn
control
polypeptid
surprisingli
flagellin
emptysapn
particl
higher
activ
recombin
flagellin
alon
sapn
glase
adjuv
confer
robust
protect
gondii
hlaa
transgen
mice
result
shown
fig
immun
mice
either
cellelicit
sapn
glase
adjuv
emptysapn
glase
adjuv
adjuv
alon
padr
alon
pb
challeng
week
last
immun
type
ii
strain
gondii
express
luciferas
brain
mice
imag
xenogen
camera
day
challeng
tachyzoit
figur
b
show
luminesc
gondii
mice
immun
cellelicit
sapn
plu
glase
significantli
lower
mice
immun
control
emptysapn
plu
glase
glase
alon
padr
alon
pb
find
correl
reduct
number
cyst
per
brain
mice
receiv
cellelicit
sapn
plu
glase
adjuv
fig
improv
vaccin
deliveri
approach
elicit
cellular
immun
respons
gondii
need
previou
studi
defin
panel
octamernonam
peptid
restrict
mhc
class
molecul
peptid
epitop
bind
elicit
respons
cell
isol
hla
individu
class
supermotif
present
essenti
human
popul
worldwid
differ
frequenc
differ
region
given
glase
adjuv
pool
peptid
abl
protect
graph
show
count
spot
splenocyt
untreat
emptysapn
glase
group
mice
gla
design
glase
figur
p
elispot
compar
control
haplotyp
specif
hla
supermotif
transgen
mice
protect
measur
surviv
reduc
parasit
burden
capabl
control
abil
peptid
protein
selfassembl
particl
welldefin
size
shape
allow
us
design
mechan
chemic
stabl
particl
sapn
combin
strong
immunogen
effect
live
attenu
vaccin
high
specif
elicit
immun
respons
proteinbas
vaccin
resembl
viru
capsid
appar
sapn
great
potenti
serv
platform
vaccin
beyond
abil
present
antigen
repetit
manner
contrast
live
attenu
vaccin
sapnderiv
vaccin
pose
signific
risk
infect
versatil
flexibl
design
lead
better
biophys
immunolog
properti
furthermor
bacteri
protein
express
purif
selfassembl
nanoparticl
reduc
time
need
largescal
vaccin
product
herein
use
sapn
present
immunogen
peptid
epitop
host
immun
system
base
assembl
five
protect
ctl
restrict
supertyp
addit
univers
helper
epitop
padr
epitop
flank
cterminu
nkaaa
spacer
promot
optim
immunogen
process
data
show
potent
immunogen
high
secret
splenocyt
stimul
peptid
immun
vivo
exposur
vitro
separ
studi
found
sapn
contain
flagellin
protect
better
influenza
sapn
without
flagellin
flagellin
scaffold
becam
sapn
platform
go
forward
activ
assay
sapn
flagellin
scaffold
show
good
stimul
howev
activ
reduc
compar
emptysapn
could
due
interfer
present
cellrestrict
epitop
epitop
string
engin
flagellin
molecul
replac
flagellin
domain
thu
futur
work
util
approach
engin
differ
sapn
construct
optim
process
immunogen
vaccin
constitu
propos
mechan
induc
innat
immun
sapn
ligat
gla
emuls
flagellin
surfac
sapn
mccoy
et
al
data
suggest
cross
present
stimul
epitop
sapn
fig
glase
use
sapn
success
immun
p
falciparum
elicit
antibodi
cell
wherea
sapn
without
glase
effect
dl
pb
unpublish
result
adjuv
safe
primat
enter
clinic
trial
human
despit
remark
protect
provid
sapn
vaccin
studi
brain
cyst
still
detect
thu
potenti
improv
induct
protect
immun
respons
could
made
addit
separ
nanoparticl
cellelicit
epitop
variou
gondii
protein
sever
parasit
life
stage
fig
seaport
cell
line
respons
flagellin
sapn
seaport
celllin
expos
vari
concentr
indic
protein
level
stimul
determin
level
seap
express
fold
increas
seap
express
protein
sampl
nontreat
control
error
bar
standard
error
mean
twoway
anova
model
fit
protein
concentr
type
factor
signific
protein
concentr
type
interact
p
indic
differ
across
type
depend
concentr
differ
across
concentr
vari
type
specif
nt
statist
signific
differ
across
type
two
lowest
concentr
signific
differ
type
ngml
concentr
p
subsequ
pairwis
contrast
concentr
found
restrict
group
recombin
protein
without
flagellin
significantli
differ
group
case
except
restrict
vs
comparison
ngml
concentr
addit
concentr
emptysapn
significantli
differ
greater
signific
concentr
effect
protein
type
p
except
restrict
p
prevent
toxoplasmosi
human
nanovaccin
k
el
bissati
et
al
potenti
bcell
epitop
stimul
potent
antibodi
respons
cellmedi
immun
cytolyt
cell
product
consid
desir
primari
protect
immun
respons
nonetheless
antibodi
may
contribut
protect
addit
micronem
protein
mic
protein
induc
antibodi
neutral
adhes
invas
block
complement
fix
could
improv
protect
play
signific
part
attach
penetr
host
cell
parasit
mic
recent
use
recombin
vaccin
show
promis
protect
level
also
stimul
il
product
mice
possibl
protein
could
also
engin
separ
sapn
yield
multisapn
vaccin
protect
toxoplasmosi
earlier
studi
provid
support
use
glase
adjuv
wide
varieti
protein
vaccin
includ
evalu
p
falciparum
sapn
vaccin
demonstr
glase
essenti
improv
immunogen
vs
relat
sapn
dl
pb
unpublish
studi
involv
present
antigen
protect
phylogenet
relat
apicomplexan
malaria
parasit
nonhuman
primat
found
glase
need
immun
primat
even
case
mice
earlier
work
separ
constitu
glase
use
gla
alon
call
glaaf
prepar
aqueou
formul
formul
contain
emuls
extra
excipi
equival
gla
glase
glaaf
se
alon
glase
formul
compar
earlier
studi
almost
differ
system
valu
use
gla
se
togeth
proven
tabl
work
advanc
clinic
demonstr
efficaci
safeti
studi
gla
se
formul
administ
togeth
leverag
extens
earlier
experi
produc
glase
adjuv
sapn
vaccin
gondii
work
new
sapndesign
flagellin
molecul
integr
part
sapn
scaffold
fig
without
cellelicit
epitop
sapn
scaffold
lack
epitop
confer
small
amount
protect
compar
scaffold
inclus
peptid
possibl
creat
relev
separ
control
without
flagellin
scaffold
hla
bind
peptid
intercal
flagellin
molecul
shown
fig
locat
epitop
within
protein
sequenc
shown
critic
arrang
peptid
epitop
polypeptid
induc
robust
immun
deconvolut
peptid
compon
shown
certain
epitop
alon
may
differ
toxic
separ
peptid
el
bissati
mcleod
et
al
prepar
alreadi
know
adjuv
polypeptid
protect
studi
describ
separ
manuscript
also
found
hla
class
interact
peptid
specif
hla
hla
supermotif
demonstr
mous
macrophag
present
peptid
hla
cell
five
epitop
well
fulllength
protein
origin
character
determin
well
conserv
protein
especi
specif
peptid
includ
across
multipl
strain
genet
diverg
parasit
differ
geograph
region
tabl
genet
diverg
strain
fig
support
use
immunosens
approach
approach
creat
singl
protein
contain
relev
epitop
includ
extran
epitop
potenti
harm
certain
gondii
epitop
known
far
fewer
polymorph
smaller
octam
nonam
peptid
tabl
fulllength
protein
tabl
fig
good
bind
octamernonam
three
epitop
among
differ
genet
isol
tabl
predict
bind
score
peptid
mani
genet
polymorph
strain
high
two
peptid
tabl
contrast
would
take
mani
fulllength
variant
obtain
good
geograph
coverag
either
polymorph
protein
peptid
octamernonam
critic
protect
provid
conceptu
support
use
immunosens
approach
make
vaccin
potenti
work
well
parsimoni
mani
geograph
area
recent
data
concern
uniqu
process
gondii
protein
human
cell
quit
remark
longer
like
decoy
peptid
bind
natur
infect
cell
make
target
immunosens
approach
begin
human
cell
use
hla
transgen
mice
especi
valuabl
creat
vaccin
peopl
rather
mice
critic
consider
import
beyond
vaccin
protect
organ
one
want
broad
util
across
differ
demograph
worldwid
work
toward
substanti
diseas
burden
toxoplasmosi
global
clinic
problem
data
studi
human
cell
mice
work
consid
togeth
demonstr
robust
practic
use
model
system
antigen
process
present
human
mice
differ
well
known
exampl
shown
elegantli
recent
human
murin
tapasin
diverg
sequenc
tapasin
chaperon
mhc
class
molecul
newer
murin
model
human
tapasin
proteasom
might
improv
vaccin
potenc
relev
human
vaccin
develop
altern
optim
cleavag
site
base
human
infect
use
human
pbmc
may
work
effect
hlaa
mice
comparison
test
futur
studi
signific
differ
mice
human
murin
model
imperfect
predictor
vaccin
perform
human
apart
differ
hla
tapasin
variant
erap
differ
erap
mice
human
caus
differ
process
present
differ
mice
human
includ
differ
total
blood
volum
rate
metabol
skin
compositionabsorpt
rate
differ
tlr
specif
well
basic
differ
murin
human
cell
exampl
human
cell
express
class
ii
mhc
mous
cell
nonetheless
relat
question
whether
hla
transgen
mice
good
approxim
human
respons
sett
et
al
made
follow
comment
despit
differ
issu
consid
detail
practic
studi
confirm
although
ought
differ
actual
data
peer
review
studi
show
littl
differ
human
mice
blood
liver
transplant
modif
also
still
imperfect
human
mous
system
yet
work
realli
well
demonstr
practic
feasibl
vaccin
develop
fda
requir
anim
vivo
immunogen
data
ind
submiss
vaccin
develop
follow
requir
vaccin
creat
includ
viral
vector
vlpbase
vaccin
date
system
allow
skip
anim
test
step
vaccin
eg
viral
viruslik
particl
protein
bacteri
gener
immun
respons
anim
model
immun
respons
provid
preliminari
data
prior
studi
nonhuman
primat
human
approach
permit
one
conclud
vaccin
safe
activ
even
anim
model
absolut
predict
precis
human
correl
although
would
ideal
found
approach
appear
provid
insight
work
effect
approach
includ
use
bioinformat
test
human
cell
immunogen
test
downselect
peptid
reassembl
protein
linker
design
proper
cleavag
follow
test
efficaci
safeti
use
hla
transgen
mice
approach
shown
data
herein
previou
foundat
experi
also
mani
other
use
system
immunogen
peptid
polypeptid
dna
rna
human
cell
first
extend
murin
cell
follow
protect
measur
reduc
parasit
burden
enhanc
surviv
although
imperfect
consider
prior
support
support
recent
studi
use
hla
transgen
mice
obviat
problem
heterogen
mhc
supermotif
parasit
isol
proven
practic
manner
vaccin
develop
issu
genet
polymorph
well
potenti
harm
constitu
amplifi
fulllength
natur
protein
tabl
fig
thu
choic
peptid
suffici
interact
hla
molecul
present
human
popul
made
use
bioinformat
ration
parsimoni
manner
approach
consid
parasit
genet
variat
induct
immunosens
manner
prove
valuabl
develop
vaccin
human
inclus
flagellin
immunogen
serv
potenti
adjuv
experi
flagellin
safe
effect
adjuv
preclin
anim
studi
also
effect
use
immun
younger
older
person
clinic
trial
influenza
vaccin
robust
literatur
describ
studi
mechan
wherebi
ligand
function
adjuv
summari
studi
show
sapnprotein
chain
five
cellelicit
mhc
class
epitop
gondii
mhc
class
ii
epitop
padr
refold
form
nanoparticl
use
hlaa
transgen
mice
demonstr
sapn
emulsifi
glase
adjuv
elicit
protect
mhc
class
respons
thu
work
demonstr
develop
improv
assembl
peptid
cross
present
cell
elicit
epitop
fig
vaccin
prevent
toxoplasmosi
ksfkdilpk
stfwpcllr
avvsllrllk
ssayvfsvk
amltafflr
padr
univers
helper
epitop
akfvaawtlkaaa
use
vaccin
construct
infecti
diseas
research
institut
seattl
washington
synthes
agonist
adjuv
call
glase
prepar
use
stabl
oilinwat
emuls
method
use
dna
code
nanoparticl
construct
similar
describ
earlier
work
briefli
prepar
use
standard
molecular
biolog
procedur
describ
earlier
work
laboratori
babapoor
et
al
specif
plasmid
contain
dna
code
protein
sequenc
use
construct
clone
restrict
site
sapn
express
plasmid
use
sapn
construct
develop
describ
earlier
briefli
construct
compos
pentamer
coiledcoil
tryptophan
zipper
zipper
link
glycin
residu
trimer
denovo
design
leucin
zipper
coil
coil
construct
flagellin
construct
compos
domain
residu
salmonella
enterica
flagellin
structur
pdbcode
rcsb
protein
data
bank
use
extend
protein
chain
cterminu
fig
peptid
sequenc
avvsllrllknamltafflrnaaaksfkdilpkkaaassayvfsvkkaaakfvaawtlkaaakstfwpcllr
five
epitop
also
contain
padr
next
insert
domain
flagellin
polypeptid
complet
replac
domain
gener
cellelicit
sapn
call
overal
posit
charg
epitop
string
balanc
stretch
neg
charg
end
epitop
sequenc
emptysapn
gener
use
short
linker
kykdgkgddk
replac
domain
flagellin
perform
exactli
perform
describ
earlier
work
laboratori
babapoor
et
al
plasmid
transform
escherichia
coli
cell
e
coli
grown
luria
broth
ampicillin
induc
express
use
isopropyl
cell
remov
h
induct
harvest
centrifug
x
g
store
cell
pellet
thaw
cell
pellet
keep
ice
suspend
pellet
lysi
buffer
consist
urea
mm
nah
po
mm
tri
ph
mm
imidazol
mm
phosphin
tcep
sdspage
use
assess
protein
express
level
methodolog
use
earlier
use
briefli
sonic
use
lyse
cell
describ
laboratori
earlier
centrifug
g
min
use
clarifi
lysat
least
h
clear
lysat
incub
ninta
agaros
bead
qiagen
valencia
ca
usa
next
column
wash
lysi
buffer
follow
wash
buffer
contain
urea
mm
nah
po
mm
tri
ph
mm
imidazol
mm
tcep
ph
gradient
use
purifi
protein
bound
column
ph
gradient
wash
step
creat
follow
urea
mm
nah
po
mm
citrat
mm
imidazol
mm
tcep
subsequ
wash
perform
ph
elut
protein
use
lysi
buffer
ph
gradient
gradient
increas
imidazol
concentr
use
methodolog
describ
earlier
work
specif
refold
protein
first
rebuff
follow
condit
urea
mm
tri
ph
mm
nacl
glycerol
mm
edta
solut
concentr
mgml
protein
ad
buffer
solut
without
urea
final
concentr
mgml
quick
refold
first
screen
use
quick
dilut
denatur
urea
nativ
urea
buffer
condit
trigger
refold
protein
use
neg
stain
transmiss
electron
microscopi
differ
resolut
analyz
solut
next
use
screen
optim
refold
condit
perform
smaller
sampl
size
ph
ionic
strength
vitro
respons
assay
method
use
recent
work
activ
assess
sapn
describ
recent
test
done
use
stabli
transfect
hek
cell
line
novu
biolog
littleton
co
test
mycoplasma
authent
str
profil
follow
cell
line
stabli
cotransfect
cell
line
express
secret
alkalin
phosphatas
seap
report
gene
transcript
control
respons
element
fourteen
thousand
cell
per
well
seed
plate
passag
h
later
remov
growth
media
growth
media
replac
dmem
high
glucos
hyclon
logan
ut
contain
either
sapn
recombin
flagellin
novu
biolog
concentr
ngml
triplic
media
alon
present
control
well
well
expos
stimulu
h
supernat
collect
use
determin
whether
seap
present
determin
report
assay
kit
seap
novu
biolog
done
use
manufactur
instruct
mediaonli
control
use
normal
seap
activ
use
determin
construct
triplic
determin
util
experiment
condit
mice
creat
describ
earlier
method
ident
use
earlier
work
specif
hlaa
b
transgen
femal
mice
gener
bred
produc
pharmexaepimmun
san
diego
ca
embryorederiv
tacon
jax
laboratori
coloni
expand
maintain
produc
isol
univers
chicago
mice
express
chimer
gene
call
hlaa
b
transgen
chimer
gene
consist
domain
hlaa
domain
b
mice
week
age
experi
mice
maintain
spf
condit
throughout
studi
perform
institut
anim
care
use
committe
univers
chicago
review
approv
oversight
assess
immunogen
sapn
mice
hlaa
transgen
inocul
intramusculari
inject
sapn
emulsifi
agonist
ie
glase
immun
administ
three
time
week
interv
experi
mice
challeng
challeng
day
postimmun
specif
challeng
intraperiton
use
type
ii
parasit
elispot
assay
determin
murin
splenocyt
immun
respons
perform
describ
earlier
work
provid
foundat
present
studi
specif
spleen
harvest
day
immun
follow
initi
press
screen
allow
format
suspens
singlecel
erythrocyt
deplet
suspens
akc
lysi
buffer
mm
nh
cl
mm
khco
mm
edta
use
deplet
rbc
hank
balanc
salt
solut
hbss
use
wash
splenocyt
twice
splenocyt
resuspend
supplement
mm
lglutamax
murin
splenocyt
elispot
assay
perform
describ
earlier
done
use
antimous
mab
biotinyl
antimous
mab
well
splenocyt
plate
mabtech
cincinnati
oh
sourc
antibodi
reagent
use
perform
elispot
assay
minimum
three
replic
well
use
plate
cell
condit
describ
earlier
measur
spotform
cell
per
murin
splenocyt
bioluminesc
imag
determinin
outcom
type
ii
parasit
challeng
imag
mice
infect
fluc
tachyzoit
strain
gondii
describ
earlier
work
twentyon
day
challeng
vivo
imag
system
ivi
xenogen
alameda
ca
allow
us
visual
luciferin
inject
retroorbit
interact
luciferas
parasit
mice
anesthet
anesthesia
perform
rich
induct
chamber
isofluran
imag
took
place
min
receiv
luciferin
live
imag
softwar
xenogen
use
assess
photon
emiss
pseudocolor
represent
light
intens
mean
photonsregion
interest
repres
parasit
burden
imag
mous
experi
replic
minimum
two
time
earlier
work
group
use
five
mice
enumer
cyst
mous
brain
type
ii
parasit
challeng
mous
brain
collect
day
homogen
ml
salin
nacl
homogen
use
count
tissu
cyst
microscop
describ
earlier
cyst
count
multipli
product
use
determin
number
tissu
cyst
per
brain
statist
analys
addit
detail
concern
anim
model
differ
group
previous
describ
mean
sd
use
express
data
p
valu
consid
statist
signific
result
sampl
size
vivo
studi
select
abl
detect
signific
differ
luminesc
base
prior
studi
per
group
power
detect
deviat
differ
group
per
group
power
detect
deviat
differ
group
femal
mice
bred
util
randomli
select
differ
group
agematch
differ
group
within
experi
blind
experi
vivo
experi
mice
per
group
vitro
experi
mice
per
group
provid
splenocyt
experi
replic
least
twice
repres
experi
least
separ
trial
shown
data
exclud
analys
data
support
find
studi
avail
toxodb
http
toxodborgtoxo
correspond
author
reason
request
